A novel gene–protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity-Reference-Cited by-同舟云学术

A novel gene–protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity

Published:2014-06-11 Issue:3 Volume:18 Page:458-466
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Nishida Yasunori,Kuwata Takeshi,Nitta Hiroaki,Dennis Eslie,Aizawa Masaki,Kinoshita Takahiro,Ohtsu Atsushi,Ochiai Atsushi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10120-014-0394-7.pdf

Reference27 articles.

1. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805.

2. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006;15(1):65–71.

3. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8.

4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma;Pathology International;2024-04-23

2. Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update;Archives of Pathology & Laboratory Medicine;2024-02-23

3. Effects of Extended Fixation on Advanced Gastric Cancer HER2 Status Assessment Using IHC and FISH;Anticancer Research;2024-02

4. Gastric cancer treatment: recent progress and future perspectives;Journal of Hematology & Oncology;2023-05-27

5. A CT-based radiomics signature for prediction of HER2 overexpression and treatment efficacy of trastuzumab in advanced gastric cancer;Translational Cancer Research;2022-12